X

Trial Profile

A multi-center Phase II open-label pilot study of CardiolRx™ for recurrent pericarditis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Pericarditis
Focus Therapeutic Use

Most Recent Events

28 Jun 2022 New trial record
21 Jun 2022 According to FinancialNewsMedia media release, this study will run in parallel with its multi-national Phase II acute myocarditis trial, which is expected to commence imminently.
21 Jun 2022 According to FinancialNewsMedia media release, Cardiol Therapeutics is delighted to have received IND authorization from the US FDA for its flagship formulation CardiolRx in CVD. This latest authorization is for this trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com